The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for anacaulase-bcdb (Nexo Pharmaceuticals Pty Ltd)
Active ingredients
anacaulase-bcdb
Sponsor
Date of review outcome
Lapse date
Type
Orphan Drug
Dosage form(s)
Powder and gel to be mixed prior to topical application
Indication
For use as a temporary debriding agent for the removal of eschar in partial deep dermal and full thickness burns in patients requiring hospitalization
Therapeutic area
Dermatology